Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.antiviral.2016.09.003
Title: Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge
Authors: Sun, J
Ennis, J
Turner, JD
Chu, JJH 
Keywords: DEF201
EV71
Murine model
Prophylactic effects
Therapeutic effects
Adenoviridae
Animals
Antiviral Agents
Disease Models, Animal
Dose-Response Relationship, Drug
Enterovirus A, Human
Enterovirus Infections
Genetic Vectors
Hand, Foot and Mouth Disease
Interferon-alpha
Interferon-gamma
Mice
Mice, Inbred BALB C
Survival Analysis
Viral Load
Issue Date: 1-Oct-2016
Publisher: Elsevier BV
Citation: Sun, J, Ennis, J, Turner, JD, Chu, JJH (2016-10-01). Single dose of an adenovirus vectored mouse interferon-α protects mice from lethal EV71 challenge. Antiviral Research 134 : 207-215. ScholarBank@NUS Repository. https://doi.org/10.1016/j.antiviral.2016.09.003
Abstract: © 2016 Elsevier B.V. Enterovirus 71 (EV71) causes hand-foot-and-mouth diseases as well as neurological complications in young children. Interferon (IFN) can inhibit the replication of many viruses with low cytotoxic effects. Previously, an adenovirus vectored mouse interferon-α (DEF201), subtype 5, was generated by Wu et al, 2007. In this study, the antiviral effects of DEF201 against EV71 were evaluated in a murine model. 6–day-old BALB/c mice were administered a single dose of DEF201 before or after infection with lethal dose of EV71. The survival rate, clinical symptoms, tissue viral loads and histology pathogenesis were evaluated. IFN gene expression following a single dose of DEF201 maintained high concentrations of 100–9000 pg/mL for more than 7 days in mice serum. Pre-infection administration of a single dose of 106 PFU of DEF201 offered full protection of the mice against EV71 infection compared with the empty Ad5 vector control. In addition, virus load in DEF201-treated mice muscle tissue was significantly decreased as compared with empty vector control. Histopathology analysis revealed that DEF201 significantly prevented the development of severe tissue damage with reduction of viral antigen in the murine muscle tissue. Post-infection treatment at 6 h offered full protection and partial protection at 12 h, indicating that DEF201 could be used as an anti-EV71 therapeutic agent in early stage of EV71 infection. In addition, our study showed that DEF201 enhanced the neutralization ability of serum in EV71-vaccinated mice, implying that DEF201 could promote the production of specific anti-EV71 antibodies. In conclusion, single dose of DEF201 is highly efficacious as a prophylactic agent against EV71 infection in vivo.
Source Title: Antiviral Research
URI: https://scholarbank.nus.edu.sg/handle/10635/173208
ISSN: 01663542
18729096
DOI: 10.1016/j.antiviral.2016.09.003
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
18.pdfAccepted version9.86 MBAdobe PDF

OPEN

Post-printView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.